Ascendis Pharma A (ASND) FCF Margin (2012 - 2026)

Ascendis Pharma A has disclosed FCF Margin across 14 years of filings, most recently posting 3.13% for Q1 2026.

• FCF Margin for Q1 2026 came in at 3.13%, up 1105.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 12.62% (up 3652.0% YoY), and the FY2025 annual result was 17.47%, up 5799.0% from the prior year.
• FCF Margin came in at 3.13% for Q1 2026 at Ascendis Pharma A, up from 32.52% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 1.01% in Q3 2025 to a low of 1958.88% in Q2 2022.
• The 5-year median for FCF Margin is 105.72% (2024), against an average of 384.3%.
• Peak annual rise in FCF Margin reached 896274 bps in 2022, while the deepest fall reached 38138 bps in 2022.
• Ascendis Pharma A's FCF Margin stood at 597.85% in 2022, then jumped by 97 bps to 17.5% in 2023, then slumped by 97 bps to 34.53% in 2024, then advanced by 6 bps to 32.52% in 2025, then soared by 90 bps to 3.13% in 2026.
• The last three FCF Margin figures came in at 3.13% (Q1 2026), 32.52% (Q4 2025), and 1.01% (Q3 2025), per Business Quant data.